The purpose of the present study was to assess the effect of GLP-1, administered in combination with the thiazolidinedione, pioglitazone, on glucose, insulin, glucagon, free fatty acids (FFAs ...

Recently, the US FDA approved initial combination therapy ... responsible for up to 70% of the insulin response after oral glucose in healthy subjects. GLP-1 and GIP are rapidly degraded by ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists ... once their cells stop responding to insulin, the hormone that controls blood glucose.

It is a GLP-1 receptor agonist and stimulates insulin release in the presence of elevated blood glucose,” Nirosen Vijiaratnam, MD, from the department of clinical and movement neurosciences ...

today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition. Previous studies in ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition ...

Biomea Fusion (BMEA) announced the company will become a diabetes and obesity medicines company. Based on the most recent clinical trial ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.